MINDCURE makes a CAD$500,000 strategic investment in ATMA Journey Centers, an Alberta-based psychedelics-assisted mental health clinic.
MINDCURE makes a CAD$500,000 strategic investment in ATMA Journey Centers, an Alberta-based psychedelics-assisted mental health clinic.
The completed equity investment strengthens ties between MINDCURE and ATMA
Mydecine exports dried psilocybin mushrooms from Jamaica to Canada.
Novamind reports rising revenues and cash on hand of CAD$10 million.
With its (upsized) $82.875 million dollar financing, Field Trip establishes itself as one of the industry leaders in the psychedelics space.
TRIP gains access to the huge Brazilian market for its psilocybin truffles.
Optimi Health has commenced public trading (symbol "OPTI"). The Company raised CAD$20.7 million for its IPO financing.
PsyBio has commenced trading. Its focus is on drug development for the Mental Health Crisis.
MINDCURE's new Director is a veteran of capital markets.
MindMed enhances its mental health platform with the acquisition of a machine-learning digital medicine company.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now